West Pharmaceutical Services, Inc.

WHO'M
ai
Digital Profiler. Simply click the AI button
CUSIP

955306105
SEDOL

2950482
CIK

0000105770

www.westpharma.com
LEI:
FIGI: BBG000BX24N8
WST

West Pharmaceutical Services, Inc.
GICS: 35101020 · Sector: Healthcare · Sub-Sector: Medical - Instruments & Supplies
NAME
West Pharmaceutical Services, Inc.
ISIN
US9553061055
TICKER
WST
MIC
XNYS
REUTERS
WST.N
BLOOMBERG
WST US
EN 728x90
FOR INVESTORS
FOR TRADERS
Securities Trading Warrants

The X-News Explorer is the ultimate source of information for investors with an affinity for the stock market who want to get a quick and convenient overview of the current news situation of a listed company. Various newswire services are available here. If a news alert is displayed, you will find company news that may be of interest to you. This service is provided by PR-Newswire.

Tue, 29.10.2024       West Pharmaceutical
US9553061055

EXTON, Pa., Oct. 29, 2024 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will present at the following conferences:

UBS Global Healthcare Conference in Rancho Pablos Verdes, California, on November 12, 2024 at 3:30 PM PSTJefferies Healthcare Conference in London, UK on Tuesday, November 19, 2024 at 1:00 PM GMTStephens Annual Investment Conference in Nashville, TN on Thursday, November 21, 2024 at 10:00 AM CST
Thu, 24.10.2024       West Pharmaceutical
US9553061055

- Conference Call Scheduled for 9 a.m. EDT Today -

EXTON, Pa., Oct. 24, 2024 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) today announced its financial results for the third-quarter 2024 and declared a fourth-quarter 2024 dividend.

Third-Quarter 2024 Summary (comparisons to prior-year period)

Net sales of $746.9 million declined 0.1%; organic net sales decline was 0.5%.Reported-diluted EPS of $1.85, compared to $2.14 in the same period last year.Adjusted-diluted EPS of $1.85, compared to $2.16 in the same period last year.As a result of favorable currency movements, the Company increased its full year 2024 net sales guidance range to $2.875 billion to $2.905 billion, up from its previous guidance range of $2.870 billion to $2.900 billion.The Company increased its full-year 2024 adjusted-diluted EPS guidance range to $6.55 to $6.75, up from its previous guidance range of $6.35 to $6.65.The Company also announced that its Board of Directors has approved a fourth-quarter 2024 dividend of $0.21 per share, a 5.0% increase over the $0.20 per share paid in each of the four preceding quarters. This is the thirty-second consecutive annual increase in the Company's dividend. The dividend will be paid on November 20, 2024, to shareholders of record as of November 13, 2024.
Tue, 22.10.2024       West Pharmaceutical
US9553061055

EXTON, Pa., Oct. 22, 2024 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced participation in the 2024 PDA Universe of Pre-Filled Syringes and Injection Devices Conference in Phoenix, AZ to showcase its leadership and expertise on industry challenges and trends in packaging and containment. 

Thu, 10.10.2024       West Pharmaceutical
US9553061055

EXTON, Pa., Oct. 10, 2024 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will release third-quarter financial results before the market opens on Thursday, October 24, 2024, and will follow with a conference call to discuss the results and business expectations at 9:00 a.m. Eastern Time.

Wed, 09.10.2024       West Pharmaceutical
US9553061055

EXTON, Pa., Oct. 9, 2024 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, is pleased to announce that it has been awarded the Heart of Pharma Award at the 2024 CPHI Awards for its partnership with Fox Chase Cancer Center, a part of the Temple University Health System. This award recognizes companies, individuals, and initiatives which nurture philanthropic, ethical and community-based ventures. West was announced the winner during an awards ceremony on the opening night of CPHI Worldwide on October 8 in Milan, Italy.

Mon, 07.10.2024       West Pharmaceutical
US9553061055

EXTON, Pa., Oct. 7, 2024  /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced its participation at CPHI Worldwide in Milan, Italy to showcase leadership and expertise on industry challenges and trends in packaging and containment.

This year, West will highlight its industry expertise through a technical-focused presentation:

Thu, 05.09.2024       West Pharmaceutical
US9553061055

EXTON, Pa., Sept. 5, 2024 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will present at the Bank of America Global Healthcare Conference in London, UK on Wednesday, September 18, 2024, at 9:55 AM BST.

A live audio webcast of the event will be available in the "Investors" section of the Company's website at www.westpharma.com. Replay of the webcasts will be available for approximately 90 days after the events. 

Thu, 25.07.2024       West Pharmaceutical
US9553061055

- Conference Call Scheduled for 9 a.m. EDT Today -

EXTON, Pa., July 25, 2024 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) today announced its financial results for the second-quarter 2024 and updated full-year 2024 financial guidance.

Second-Quarter 2024 Summary (comparisons to prior-year period)

Net sales of $702.1 million declined 6.9%; organic net sales declined 5.9%.Reported-diluted EPS of $1.51, compared to $2.06 in the same period last year.Adjusted-diluted EPS of $1.52, compared to $2.11 in the same period last year. The Company is updating full-year 2024 net sales guidance to a range of $2.870 billion to $2.900 billion, compared to a prior range of $3.000 billion to $3.025 billion.The Company is updating full-year 2024 adjusted-diluted EPS guidance to a range of $6.35 to $6.65, compared to a prior range of $7.63 to $7.88.
Thu, 11.07.2024       West Pharmaceutical
US9553061055

EXTON, Pa., July 11, 2024 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will release second-quarter financial results before the market opens on Thursday, July 25, 2024, and will follow with a conference call to discuss the results and business expectations at 9:00 a.m. Eastern Time.

Wed, 29.05.2024       West Pharmaceutical
US9553061055

CZ's Nested Vials are designed to meet the exterior dimensions of glass standard ISO 8362-1 and offer broad compatibility with various aseptic fill-finish equipment available in the market.

EXTON, Pa., May 29, 2024 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, announced today that it will unveil its new Daikyo Crystal Zenith® (CZ) Nested Vials in Tub at the International Society for Cell and Gene Therapy (ISCT) Annual Meeting taking place in Vancouver, Canada from May 29- June 1.

We are different
OPEN FINANCIAL
DATA & KNOWLEDGE HUB
We make the difference
Information on product placements